| Bioactivity | MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist. | ||||||||||||
| Invitro | MRE-269 induces endothelium-independent vasodilation of rat extralobar pulmonary artery (EPA). MRE-269 or other IP receptor agonists including epoprostenol, iloprost, treprostinil and beraprost increase cAMP levels in hPASMC[1]. MRE-269 induces concentration-dependent vasodilation in LPA(+), LPA(-), and SPA(-)[3]. | ||||||||||||
| Name | MRE-269 | ||||||||||||
| CAS | 475085-57-5 | ||||||||||||
| Formula | C25H29N3O3 | ||||||||||||
| Molar Mass | 419.52 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|